tbuckley/cabot-search huggingface dataset:
Abstract 759: Metformin enhances the benefit of ALK inhibitors in ALK translocation-positive non-small cell lung cancer cells
Authors: Mi Young Kim, Geum Ock Kim, Dong Hoon Shin, Tae Min Kim, Jin-Soo Kim
Journal: Cancer Research (2015)

Abstract Background: Crizotinib is an effective tyrosine kinase inhibitor (TKI) against non-small cell lung cancers (NSCLCs) with anaplastic lymphoma receptor tyrosine kinase (ALK) translocation. Recently, the second generation ALK inhibitors, including alectinib (CH5424802) and ceritinib (LDK378) are actively investigated in clinical trials and show strong anti-tumor effect both in crizotinib-naïve and refractory NSCLC patients with ALK translocation. Unfortunately, the efficacy of these ALK inhibiting TKIs is limited due to primary and acquired resistance to these agents. Metformin is a widely used antidiabetic drug and shows promising anti-tumor effect in several cancers. Here, we define a therapeutic synergism between ALK inhibitors and metformin. Material and Methods: NSCLC cells with ALK translocation-positive (ALK+) and crizotinib-sensitive H2228 and H3122, and ALK+, crizotinib-resistant SNU2535 and ALK translocation-negative H226 were evaluated. We assessed response of these NSCLC cells to crizotinib, alectinib and ceritinib alone or in combination with metformin by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay and anchorage independent growth in soft agar. Combination indices (Cis) were calculated by CalcusynTM (Biosoft, Cambridge, UK). Western blots were performed to assess biochemical changes, especially those related with ALK signaling components. Results: The combination of ALK inhibitors with metformin induced a strong anti-proliferative effect only in ALK+ cell lines (CI of crizotinib and metformin: 0.31 - 0.79, CI of alectinib and metformin: 0.40 - 0.86, CI of ceritinib and metformin: 0.38 - 0.65). Alectinib and ceritinib effectively inhibited growth of crizotinib-resistant SNU2535, while crizotinib did not. Notably, synergistic effects of these ALK inhibitors and metformin were also shown in SNU2535 cells. Compared to ALK inhibitor alone, the combination of ALK inhibitor plus metformin resulted in decreased phosphorylation of ALK and downstream targets, such as AKT or ERK, both in crizotinib-sensitive and resistant ALK+ cells. Conclusion: Collectively, these data support that ALK inhibitors and metformin are synergistic in ALK+ NSCLC cells. Resistance to crizotinib as well as alectinib and ceritinib might be overcome by addition of metformin. Citation Format: Mi Young Kim, Geum Ock Kim, Dong Hoon Shin, Tae Min Kim, Jin-Soo Kim. Metformin enhances the benefit of ALK inhibitors in ALK translocation-positive non-small cell lung cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 759. doi:10.1158/1538-7445.AM2015-759
Functional Analysis Of SEPT9-ABL1 Chimeric Fusion Gene Derived From T-Prolymphocytic Leukemia
Authors: Kawai Hidetsugu, Matsushita Hiromichi, Suzuki Rikio, Sheng Yin, Lu Jun, Matsuzawa Hideyuki, Yahata Takashi, Kaneko Mitsuyo, Tsukamoto Hideo, Kawada Hiroshi, Ogawa Yoshiaki, Kiyoshi Ando
Journal: Blood (2013)
TCT-701 Mitral Transapical Transcatheter Valve-in-Valve Implantation Using The Braile Inovare Prosthesis
Authors: Diego F. Gaia, Matheus S. Santos, Danny Dvir, Joao R. Breda, Murilo Macedo, Carolina Baeta, Jose Augusto Marcondes, Jose Honorio Palma, Enio Buffolo
Journal: Journal of the American College of Cardiology (2015)
GW27-e1138 Diagnostic performance of delta cardiac troponin levels for acute non-st-elevation myocardial infarction
Authors: Jiang Peng, Ye Zi, Huang Ying-xiong, Xiong Yan, Cai Rui-bing, Xiao Xiao-yong, Huang Zhen-hua, Zhan Hong
Journal: Journal of the American College of Cardiology (2016)
Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531
Authors: Jessica Pollard, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Wang, Jason Joaquin, Susana C. Raimondi, Betsy A. Hirsch, Lillian Sung, Richard Aplenc, Irwin D. Bernstein, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2015)
Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE® Antibody Construct AMG 330
Authors: Hauke Stamm, Felix Klingler, Daniela Pende, Eik Vettorazzi, Michael Heuser, Ulrike Mock, Carsten Bokemeyer, Roman Kischel, Sabine Stienen, Matthias Friedrich, Michael Lutteropp, Dirk Nagorsen, Jasmin Wellbrock, Walter Fiedler
Journal: Blood (2015)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
Authors: Sabine Tejpar, Sebastian Stintzing, Fortunato Ciardiello, Josep Tabernero, Eric Van Cutsem, Frank Beier, Regina Esser, Heinz-Josef Lenz, Volker Heinemann
Journal: JAMA Oncology (2016)

Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct.
TCT-655 Should we perform carotid artery screening before aortic valve replacement?
Authors: Jose F. Condado, Hanna A. Jensen, Aneel Maini, Yi-An Ko, Mohammad H. Rajaei, Lillian L. Tsai, Chandan Devireddy, Bradley G. Leshnower, Kreton Mavromatis, Eric Sarin, James Stewart, Robert Guyton, Vasilis Babaliaros, Amy E. Simone, Patricia Keegan, Peter C. Block, Vinod Thourani
Journal: Journal of the American College of Cardiology (2015)
Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL)
Authors: A. A. Tarhini, S. Land, F. Lim, G. J. Kiefer, L. Pietragallo, R. A. Pinkerton, M. Sulecki, D. Meisner, P. M. Schaefer, K. A. Foon
Journal: Journal of Clinical Oncology (2006)

6599 Background: Recent data reporting results of FCR therapy in previously untreated advanced CLL patients (F-25 mg/m 2 d1–3 q 4wk; C-250 mg/m 2 d 1–3 q 4wk; R-500 mg/m 2 d1 q 4wk for 6 cycles) demonstrated complete remission (CR) of 70% and overall response (OR) of 95% (J Clin Oncol 2005;23:4079). The major toxicity was grade 3/4 neutropenia during 52% of courses. One approach to decrease neutropenia without compromising efficacy could be by reducing the doses of F and C and increasing the dose of R as high-dose R has been reported to be more efficacious in CLL. Methods: We conducted a phase II study for previously untreated advanced CLL patients treated with mFCR (F-20mg/m 2 d1–3 q 4 wk; C-150 mg/m 2 d1–3 q 4 wk; R-500mg/m 2 d1 and d14 q 4wks; maintenance R-500 mg/m 2 q 3 months until progression). A Simon two-stage design was used where 15 patients were accrued in the first stage and because of acceptable toxicity and response rate in stage I an additional 35 patients will be treated. The primary endpoint was response rate. Results: Twenty patients (13 male, 7 female), age 36–85 years (median 59) were treated with a total of 105 mFCR courses. All 20 patients were evaluable for toxicity. Grade 3/4 neutropenia occurred during 11(10.5%) courses. There were no episodes of neutropenic fever. Grade 3/4 thrombocytopenia occurred during 4 (3.8%) courses. Two patients are currently on study and not evaluable for response and among the 18 evaluable patients, the CR was 68%, PR was 32% with an OR of 100%. Eleven of the 12 CR patients had no evidence of CD5 + /CD19 + coexpressing cells in their bone marrow after therapy and one had &lt;1%; all 12 were NED by CT scan. Conclusions: Our preliminary results suggest mFCR is highly effective with considerably less grade 3/4 neutropenia than standard FCR. Complete responders had minimal residual disease in their bone marrow following mFCR. [Table: see text]
TCT-657 Post-Procedural And Follow-Up Management In Patients Undergoing Transcatheter Aortic Valve Implantation: Results From The Written (WoRldwIde TAVI ExpieNce) Survey
Authors: Luis Nombela-Franco, Enrico Cerrato, Helene Eltchaninoff, Henrique B. Ribeiro, Lars Søndergaard, Marco Barbanti, Fabian Nietlispach, Peter De Jaegere, Pierfrancesco Agostoni, Pilar Jimenez-Quevedo, Ramiro Trillo, Claudio Moretti, Olaf Wendler, Gabriel Maluenda, Antonio Fernandez-Ortiz, Corrado Tamburino, Carlos Macaya, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Authors: Daniel Turner, Andres Gonzalez, Leslie Pettiford, Amy Meacham, Elizabeth Wise, Raphael C Bosse, Dai Chaplin, Jack W. Hsu, Randy A Brown, John W Hiemenz, Maxim Norkin, John R Wingard, Christopher R Cogle
Journal: Blood (2013)
Polymorphisms in the F Pocket of HLA–B27 Subtypes Strongly Affect Assembly, Chaperone Interactions, and Heavy‐Chain Misfolding
Authors: David B. Guiliano, Helen North, Eleni Panayoitou, Elaine C. Campbell, Kirsty McHugh, Fiona G. M. Cooke, Marine Silvestre, Paul Bowness, Simon J. Powis, Antony N. Antoniou
Journal: Arthritis & Rheumatology (2016)

HLA-B27 is associated with the inflammatory spondyloarthritides (SpA), although subtypes HLA-B*27:06 and HLA-B*27:09 are not. These subtypes differ from the HLA-B*27:05 disease-associated allele primarily at residues 114 and 116 of the heavy chain, part of the F pocket of the antigen-binding groove. Dimerization of HLA-B27 during assembly has been implicated in disease onset. The purpose of this study was to investigate the factors that influence differences in dimerization between disease-associated and non-disease-associated HLA-B27 alleles.HLA-B*27:05 and mutants resembling the HLA-B*27:06 and 09 subtypes were expressed in the rat C58 T cell line, the human CEM T cell line and its calnexin-deficient variant CEM.NKR. Immunoprecipitation, pulse-chase experiments, flow cytometry, and immunoblotting were performed to study the assembly kinetics, heavy-chain dimerization, and chaperone associations.By expressing HLA-B*27:05, 06-like, and 09 alleles on a restrictive rat transporter associated with antigen processing background, we demonstrate that a tyrosine expressed at p116, either alone or together with an aspartic acid residue at p114, inhibited HLA-B27 dimerization and increased the assembly rate. F-pocket residues altered the associations with chaperones of the early major histocompatibility complex class I folding pathway. Calnexin was demonstrated to participate in endoplasmic reticulum (ER) stress-mediated degradation of dimers, whereas the oxidoreductase ERp57 does not appear to influence dimerization.Residues within the F pocket of the peptide-binding groove, which differ between disease-associated and non-disease-associated HLA-B27 subtypes, can influence the assembly process and heavy-chain dimerization, events which have been linked to the initiation of disease pathogenesis.
Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine and radiation efficacy in borderline resectable (BR) pancreatic cancer.
Authors: Niraj K. Gupta, Kirpal Singh, Timothy Glass, Chad Davis, Mark Lybik, Christopher Leagre, Robert H. Liebross, Thomas Dugan, Mark Edwards, Stanley Givens, Julia Compton, Thomas Tigges, Vincent Flanders, Vinay Mathavan, Andrew Isch, Dave Reeves, Gabriel Arevalo, Michael Rowe, Douglas Kaderabek, Maurice Arregui
Journal: Journal of Clinical Oncology (2016)

e15698 Background: Neo-adjuvant approach is emerging as a standard in the management of BR pancreatic cancer patients and various strategies have been described in the literature. We report our experience with a combination of nab-Paclitaxel and Gemcitabine followed by concurrent Capecitabine and radiation therapy in BR pancreatic cancer patients. . Methods: A prospectively maintained database of patients with BR pancreatic cancer undergoing neo-adjuvant treatments at our center between 01/2013- 6/2015 was reviewed. Pts were treated with Gemcitabine(1gm/m2) and nab-paclitaxel (125mg/m2) given on D1/8/15 every 28 days . Pts. were re-assessed after 2 cycles and the responding pts received 2 additional cycles. Pts. continuing to respond after 4 cycles were treated with capecitabine (825mg/m2) and radiation treatments (50.4Gy). Results: A total of 15 patients with PS 0/1 were treated. Median age was 57 yrs (46-71) and M/F ratio was 12:3. After 2 cycles of Gem/nab-paclitaxel, none of the pts. had progressive disease. All patients completed 4 cycles of Gem/nab-paclitaxel. All 15 patients (100%) received capecitabine and radiation treatments. Responses with the neo-adjuvant treatments were; 0 CR, 4 PR, 10 SD, 1 PD. Eleven patients (73%) underwent planned resection, 3 had PD and 1 had decline in PS. Nine out of eleven (81%) patients undergoing surgery had a R0 resection. Grade-III/IV toxicities with the neo-adjuvant treatments were seen in 40% and 6 % of the pts., respectively. There was no 30 day post-op mortality, pancreatic leaks or re-operations. 12/15 (80%) patients are alive with a median follow-up of 10 months range: (4-26months). Of the 11 patients who had surgery,10 (90%) are alive, 8 (72%) have no evidence of disease and one died after 22 months. Conclusions: Nab-Paclitaxel and Gemcitabine followed by Capecitabine and radiation treatment is an effective neo-adjuvant strategy with acceptable toxicity-profile in the management of patients with good performance status diagnosed with BR pancreatic cancer.
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
Authors: Tamas Pinter, Esteban Abella, Alvydas Cesas, Adina Croitoru, Jochen Decaestecker, Peter Gibbs, Yevhen Hotko, Jacek Jassem, Galina Petrova Kurteva, Jan Novotny, Seamus O'Reilly, Tomas Salek, May F. Mo, L. Mi Rim Choi, Charles Davic Blanke
Journal: Journal of Clinical Oncology (2013)

3575 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant neutropenia. his trial was conducted to evaluate the efficacy of PEG in reducing the incidence of febrile neutropenia (FN) in pts with locally-advanced (LA) or metastatic (m)CRC receiving first-line treatment with either FOLFOX/B or FOLFIRI/B. Methods: Key eligibility: ≥ 18 years old; measurable, nonresectable CRC per RECIST 1.1. Pts were randomly assigned 1:1 to either placebo or 6 mg PEG ~24 h after ctx/B. The study treatment period included four Q2W cycles, but pts could continue their assigned regimen until progression. Pts were stratified by region (North America vs rest of world), stage (LA vs mCRC), and ctx (FOLFOX vs FOLFIRI). Estimated sample size (N = 800) was based on the expected incidence of grade 3/4 FN (primary endpoint) across the first 4 cycles of ctx/B, powered for PEG superiority over placebo. Other endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: 845 pts were randomized (Nov 2009 to Jan 2012) and received study treatment; 783 pts completed 4 cycles of ctx/B. Median age was 61 years; 512 (61%) pts were male; 819 (97%) had mCRC; 414 (49%) received FOLFOX, and 431 (51%) received FOLFIRI. Grade 3/4 FN (first 4 cycles) for placebo vs PEG was 5.7% vs 2.4%; OR 0.41; p = 0.014. A similar incidence of other ≥ grade 3 adverse events was seen in both arms (28% placebo; 27% PEG). See table for additional results. Conclusions: PEG significantly reduced the incidence of grade 3/4 FN in this pt population receiving standard ctx/B for CRC. Follow-up is ongoing. Clinical trial information: NCT00911170. [Table: see text]
Reply
Authors: Fen Huang, Yunlong Li, Wenhai Yu, Chenchen Yang
Journal: Hepatology (2016)

We thank Baechlein et al. for their comments regarding our recent study published in Hepatology.1 The zoonotic nature of hepatitis E virus (HEV) has been extensively demonstrated through the recognition of its circulation among various species. We have recently described a high prevalence of genotype 4 HEV in cows in a rural area of southwest China. These infected cows can secret the viruses into milk, which are infectious in rhesus macaque model.1 Baechlein et al. now have evaluated the presence of HEV RNA in 400 milk samples that were collected in 2008 from dairy farms in Germany. However, they did not find the presence of HEV RNA in these samples. The high prevalence of genotype 4 HEV in cows was found in a rural area with mixed farming systems, in contrast to the setting of industrialized farms in Germany. In the rural area of Yunnan Province of China, family-based small farms host diverse animals, including pigs, buffalos, cows, goats, sheep, chickens, ducks, rabbits, and dogs. This could be an important risk factor for HEV transmission among different species. However, this may not be the only factor. Because seroprevalence of HEV in cows has been described in several other regions in China, HEV RNA positivity was reported in 8% of cows on dairy farms in a province from northwest China.1 More intriguingly, a seroprevalence of 15% was described in cattle in the United States.2 Second, the difference in genotype distribution may play a role. Genotype 3 is prevalent in developed countries. Genotype 4, a more pathogenic type, is mainly reported in Asia. The prevalence and burden of genotype 4 are increasingly recognized in China. Recently, three deaths were reported during a genotype 4 HEV outbreak that occurred in China.3 However, it is not necessarily so that only genotype 4 can infect cattle. Although there is no direct evidence, exposure of cows to HEV in the United States is likely related to genotype 3.(2) Finally, RNA viruses are prone to degrade after long-term storage at –20°C. Therefore, it is recommended to detect HEV using fresh or properly stored samples. Meanwhile, more milk samples from different sanitary conditions should be tested, given that 400 samples are insufficient of representing the prevalence in the entire country. Thus, the prevalence of HEV in milk and its risk of zoonotic transmission in developed countries should be further investigated. Fen Huang, Ph.D.1 Yunlong Li, MS.c.1 Wenhai Yu, MS.c.2 Chenchen Yang, MS.c.1 1Medical Faculty Kunming University of Science and Technology Kunming, China 2Institute of Medical Biology Chinese Academy of Medical Sciences and Peking Union Medical College Kunming, China Author names in bold designate shared co-first authorship.
Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
Authors: Saad J. Sirop, Aref Al-Kali, Kebede Begna, Naseema Gangat, Louis Letendre, Luis F. Porrata, William J Hogan, Mark R Litzow, Mrinal M. Patnaik
Journal: Blood (2012)
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial
Authors: Loes van Keimpema, Frederik Nevens, Ragna Vanslembrouck, Martijn G van Oijen, Aswin L Hoffmann, Helena M Dekker, Robert A De Man, Joost P Drenth
Journal: Hepatology (2009)

Background & aims  Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results. Treatment with somatostatin analogues slowed kidney growth in patients with polycystic kidney disease (PKD) and reduced liver and kidney volume in a PKD rodent model. We evaluated the effects of lanreotide, a somatostatin analogue, in patients with polycystic liver because of autosomal-dominant (AD) PKD or autosomal-dominant polycystic liver disease (PCLD).  Methods  We performed a randomized, double-blind, placebo-controlled trial in 2 tertiary referral centers. Patients with polycystic liver (n = 54) were randomly assigned to groups given lanreotide (120 mg) or placebo, administered every 28 days for 24 weeks. The primary end point was the difference in total liver volume, measured by computerized tomography at weeks 0 and 24. Analyses were performed on an intention-to-treat basis.  Results  Baseline characteristics were comparable for both groups, except that more patients with ADPKD were assigned to the placebo group (P = .03). The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547–8665) to 4471 mL (95% CI: 542–8401 mL), in patients given lanreotide. In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613–8765 mL) to 4895 mL (95% CI: 739–9053 mL) (P   Conclusions  In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
Pericervical Injection of 99mTc-Nanocolloid Is Superior to Peritumoral Injection for Sentinel Lymph Node Detection of Endometrial Cancer in SPECT/CT
Authors: Samine Sahbai, Florin-Andrei Taran, Francesco Fiz, Annette Staebler, Sven Becker, Erich Solomayer, Diethelm Wallwiener, Christian la Fougère, Sara Brucker, Helmut Dittmann
Journal: Clinical Nuclear Medicine (2016)

Scintigraphic mapping of sentinel lymph node (SLN) is increasingly performed in patients with endometrial carcinoma although its routine clinical use is still under investigation. The purpose of this study was to compare preoperative SLN detection by means of SPECT/CT using pericervical (PC) versus hysteroscopic peritumoral (PT) injection.One hundred forty consecutive patients with endometrial carcinoma who underwent surgery and preoperative SLN SPECT/CT with Tc-nanocolloid were included. Seventy women received hysteroscopic injection at 3 PT sites, and 70 women received PC injection at 3-, 6-, 9-, and 12-o'clock positions. Each patient underwent SPECT/CT followed by modified radical hysterectomy with lymphadenectomy on the day after. Histopathological results were collected for validation.Three hundred thirty-four SLNs were detected by SPECT/CT in 106 patients (mean, 3.15; range, 1-9). The detection rate after PC nanocolloid injection was 83% versus 69% after PT injection (Pearson χ test, P = 0.049). However, PT application resulted in a higher rate of para-aortic SLNs (PC: 60% vs PT: 38% of positive scans, P = 0.02). SPECT/CT yielded an overall sensitivity of 70% for the SLN detection in women with lymph node metastases with 3 false-negative cases. Failure to detect SLN was mostly associated with uptake in the reticuloendothelial system (liver, spleen, and bone marrow) or peritoneal diffusion in both cohorts. Negative scans after PT application often showed a minor to even failing injection depot.Pericervical injection leads to a significantly better detection rate of SLN on SPECT/CT while reducing invasiveness of the injection procedure. Failure to detect SLN seems to be associated with major venous drainage.
TCT-196 The Recover Right Trial Criteria for Right Ventricular Failure: An Analysis of the SHould we emergently revascularize Occluded coronaries for Cardiogenic shock (SHOCK) Trial and Registry
Authors: Navin K. Kapur, Anuradha Lala, Noam Josephy, Yu Guo, Richard H. Karas, Daniel Burkhoff
Journal: Journal of the American College of Cardiology (2015)
Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients
Authors: John S. Welch, Allegra Petti, Christopher A. Miller, Daniel C. Link, Matthew J. Walter, Catrina C. Fronick, Robert S. Fulton, Lukas D. Wartman, Geoffrey L. Uy, Armin Ghobadi, Michael Tomasson, Iskra Pusic, Rizwan Romee, Todd A Fehniger, Keith Stockerl-Goldstein, Ravi Vij, Stephen Oh, Camille N. Abboud, Amanda F. Cashen, Mark A. Schroeder, Meagan A. Jacoby, Peter Westervelt, John F Dipersio, Richard K Wilson, Timothy J. Ley
Journal: Blood (2015)
FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Authors: Andrew G. Polson, Bing Zheng, Kristi Elkins, Jeffery Lau, Mary Ann T. Go, Suzie J. Scales, Shang-Fan Yu, Marta Chesi, P. Leif Bergsagel, Allen J. Ebens
Journal: Blood (2009)